Skip to main content

California Bill: AB 1088

Public health: kratom.

Topics

Over­medicalization
Health Freedom
Mental Health

Bill Information

MAHA Not Approved

Summary

Bill Summary

While this bill contains consumer protections (21+ age restrictions, child-resistant packaging, anti-deceptive marketing) aligned with KCPA principles, the 2% 7-OH cap doesn't distinguish between natural alkaloid content and synthetic products; it risks banning natural high-7-OH strains. FDA guidance and the research positions explicitly support distinguishing natural kratom from synthetics; this restricts alkaloid percentage regardless of source.

Why it matters to MAHA

CA AB1088 follows a flawed regulatory approach that contradicts the FDA's July 2025 guidance. Rather than targeting synthetic/concentrated 7-OH specifically, it caps all 7-OH at 2%, potentially banning natural strains that fall above this threshold. This represents health authoritarianism through alkaloid ceiling-setting rather than the transparent consumer-protection KCPA model MAHA supports, which protects against synthetics while preserving natural product access.

Introduced

01/01/2026

In Committee

01/01/2026

Failed

04/30/2026

Sponsors

Jasmeet Bains

Democratic Assemblymember (CA)

916-319-2035assemblymember.bains@assembly.ca.gov

Activity

02/20/2025

Read first time. To print.

02/21/2025

From printer. May be heard in committee March 23.

03/10/2025

Referred to Coms. on HEALTH and E.S & T.M.

04/03/2025

In committee: Hearing postponed by committee.

04/10/2025

From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.

04/21/2025

Re-referred to Com. on HEALTH.

04/21/2025

From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.

04/22/2025

Re-referred to Com. on HEALTH.

04/23/2025

From committee: Do pass and re-refer to Com. on E.S & T.M. (Ayes 16. Noes 0.) (April 22). Re-referred to Com. on E.S & T.M.

04/30/2025

From committee: Do pass and re-refer to Com. on APPR. (Ayes 7. Noes 0.) (April 29). Re-referred to Com. on APPR.

05/14/2025

In committee: Hearing postponed by committee.

05/21/2025

In committee: Set, first hearing. Referred to APPR. suspense file.

05/21/2025

Joint Rule 62(a), file notice suspended. (Page 1627.)

05/23/2025

From committee: Do pass. (Ayes 14. Noes 0.) (May 23).

05/27/2025

Read second time. Ordered to third reading.

06/02/2025

Read third time. Passed. Ordered to the Senate. (Ayes 76. Noes 0. Page 1876.)

06/03/2025

In Senate. Read first time. To Com. on RLS. for assignment.

06/11/2025

Referred to Com. on HEALTH.

Questions or suggestions?

Have questions about this bill or our legislative tracker? We'd love to hear from you. Contact us and we'll get back to you as soon as possible.